首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1160910篇
  免费   114208篇
  国内免费   1409篇
耳鼻咽喉   16620篇
儿科学   39082篇
妇产科学   29627篇
基础医学   170060篇
口腔科学   34739篇
临床医学   108317篇
内科学   228523篇
皮肤病学   31502篇
神经病学   95439篇
特种医学   45787篇
外国民族医学   216篇
外科学   178297篇
综合类   21795篇
现状与发展   1篇
一般理论   295篇
预防医学   79970篇
眼科学   25885篇
药学   92588篇
  7篇
中国医学   3812篇
肿瘤学   73965篇
  2021年   9070篇
  2020年   9957篇
  2019年   18198篇
  2018年   20766篇
  2017年   19561篇
  2016年   21383篇
  2015年   22430篇
  2014年   26486篇
  2013年   34350篇
  2012年   35504篇
  2011年   37214篇
  2010年   27691篇
  2009年   23226篇
  2008年   32972篇
  2007年   34206篇
  2006年   34758篇
  2005年   32851篇
  2004年   31426篇
  2003年   30244篇
  2002年   29232篇
  2001年   61360篇
  2000年   62861篇
  1999年   51733篇
  1998年   12674篇
  1997年   11168篇
  1996年   11168篇
  1995年   10471篇
  1994年   9492篇
  1993年   9000篇
  1992年   38058篇
  1991年   36537篇
  1990年   35994篇
  1989年   34540篇
  1988年   31087篇
  1987年   30208篇
  1986年   28414篇
  1985年   26643篇
  1984年   19358篇
  1983年   16249篇
  1982年   8948篇
  1979年   17135篇
  1978年   11477篇
  1977年   10302篇
  1975年   10124篇
  1974年   11731篇
  1973年   11345篇
  1972年   10803篇
  1971年   10154篇
  1970年   9307篇
  1969年   8992篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Quality of Life Research - The COVID-19 pandemic might add to the stressors experienced by people living with rheumatic diseases. This study aimed to examine rheumatic patients’ functional...  相似文献   
3.
Molnár  B.  Aroca  S.  Dobos  A.  Orbán  K.  Szabó  J.  Windisch  P.  Stähli  A.  Sculean  A. 《Clinical oral investigations》2022,26(12):7135-7142
Clinical Oral Investigations - To evaluate t he long-term outcomes following treatment of RT 1 multiple adjacent gingival recessions (MAGR) using the modified coronally advanced tunnel (MCAT) with...  相似文献   
4.
ObjectiveSpinal cord stimulation (SCS) is an effective treatment in failed back surgery syndrome (FBSS). We studied the effect of preimplantation opioid use on SCS outcome and the effect of SCS on opioid use during a two-year follow-up period.Materials and methodsThe study cohort included 211 consecutive FBSS patients who underwent an SCS trial from January 1997 to March 2014. Participants were divided into groups, which were as follows: 1) SCS trial only (n = 47), 2) successful SCS (implanted and in use throughout the two-year follow-up period, n = 131), and 3) unsuccessful SCS (implanted but later explanted or revised due to inadequate pain relief, n = 29). Patients who underwent explantation for other reasons (n = 4) were excluded. Opioid purchase data from January 1995 to March 2016 were retrieved from national registries.ResultsHigher preimplantation opioid doses associated with unsuccessful SCS (ROC: AUC = 0.66, p = 0.009), with 35 morphine milligram equivalents (MME)/day as the optimal cutoff value. All opioids were discontinued in 23% of patients with successful SCS, but in none of the patients with unsuccessful SCS (p = 0.004). Strong opioids were discontinued in 39% of patients with successful SCS, but in none of the patients with unsuccessful SCS (p = 0.04). Mean opioid dose escalated from 18 ± 4 MME/day to 36 ± 6 MME/day with successful SCS and from 22 ± 8 MME/day to 82 ± 21 MME/day with unsuccessful SCS (p < 0.001).ConclusionsHigher preimplantation opioid doses were associated with SCS failure, suggesting the need for opioid tapering before implantation. With continuous SCS therapy and no explantation or revision due to inadequate pain relief, 39% of FBSS patients discontinued strong opioids, and 23% discontinued all opioids. This indicates that SCS should be considered before detrimental dose escalation.  相似文献   
5.
6.
7.
8.
9.
10.
Inflammatory bowel disease (IBD) is a chronic disease that requires chronic treatment throughout the evolution of the disease, with a complex physiopathology that entails great challenges for the development of new and specific treatments for ulcerative colitis and Crohn´s disease. The anti-tumor necrosis factor alpha therapy has impacted the clinical course of IBD in those patients who do not respond to conventional treatment, so there is a need to develop new therapies and markers of treatment response. Various pathways involved in the development of the disease are known and the new therapies have focused on blocking the inflammatory process at the gastrointestinal level by oral, intravenous, subcutaneous, and topical route. All these new therapies can lead to more personalized treatments with higher success rates and fewer relapses. These treatments have not only focused on clinical remission, but also on achieving macroscopic changes at the endoscopic level and microscopic changes by achieving mucosal healing. These treatments are mainly based on modifying signaling pathways, by blocking receptors or ligands, reducing cell migration and maintaining the integrity of the epithelial barrier. Therefore, this review presents the efficacy and safety of the new treatments that are currently under study and the advances that have been made in this area in recent years.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号